Emerging pathways driving early synaptic pathology in Alzheimer's disease.

ABSTRACT: The current state of the AD research field is highly dynamic is some respects, while seemingly stagnant in others. Regarding the former, our current lack of understanding of initiating disease mechanisms, the absence of effective treatment options, and the looming escalation of AD patients is energizing new research directions including a much-needed re-focusing on early pathogenic mechanisms, validating novel targets, and investigating relevant biomarkers, among other exciting new efforts to curb disease progression and foremost, preserve memory function. With regard to the latter, the recent disappointing series of failed Phase III clinical trials targeting Aβ and APP processing, in concert with poor association between brain Aβ levels and cognitive function, have led many to call for a

SUBMITTER: Briggs CA 

PROVIDER: S-EPMC5303639 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature